{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T16:39:31Z","timestamp":1776184771942,"version":"3.50.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["zefq-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Zeitschrift f\u00fcr Evidenz, Fortbildung und Qualit\u00e4t im Gesundheitswesen"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.zefq.2023.04.004","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T15:35:33Z","timestamp":1685460933000},"page":"95-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Kontroverse um die Alzheimer-Fr\u00fchdiagnostik \u2013 eine literaturbasierte \u00dcbersicht \u00fcber die Vor- und Nachteile"],"prefix":"10.1016","volume":"179","author":[{"given":"Elmar","family":"Gr\u00e4\u00dfel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natascha","family":"Lauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.zefq.2023.04.004_b0005","unstructured":"World Health Organization, Dementia: Key facts. https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/dementia, 2022 (accessed 18 December)."},{"issue":"10113","key":"10.1016\/j.zefq.2023.04.004_b0010","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/S0140-6736(17)31363-6","article-title":"Dementia prevention, intervention, and care","volume":"390","author":"Livingston","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.zefq.2023.04.004_b0015","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"15","key":"10.1016\/j.zefq.2023.04.004_b0020","doi-asserted-by":"crossref","first-page":"8598","DOI":"10.3390\/ijms23158598","article-title":"Biomarkers for the diagnosis of Alzheimer\u2019s disease in clinical practice: the role of CSF biomarkers during the evolution of diagnostic criteria","volume":"23","author":"Dulewicz","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.zefq.2023.04.004_b0025","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1474-4422(17)30159-X","article-title":"Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers","volume":"16","author":"Frisoni","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.zefq.2023.04.004_b0030","doi-asserted-by":"crossref","first-page":"371","DOI":"10.14283\/jpad.2021.23","article-title":"Diagnosis of early Alzheimer\u2019s disease: clinical practice in 2021","volume":"8","author":"Porsteinsson","year":"2021","journal-title":"J Prev Alzheimer's Dis"},{"issue":"3","key":"10.1016\/j.zefq.2023.04.004_b0035","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/j.zefq.2023.04.004_b0040","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.1016\/j.zefq.2023.04.004_b0045","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"6","key":"10.1016\/j.zefq.2023.04.004_b0050","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","article-title":"Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group","volume":"20","author":"Dubois","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.zefq.2023.04.004_b0055","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation (CBER). Early Alzheimer\u2019s disease: developing drugs for treatment, Guidance for industry. https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM596728.pdf, 2018 (accessed 06 January 2022)."},{"key":"10.1016\/j.zefq.2023.04.004_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113320","article-title":"Alzheimer\u2019s disease and its treatment by different approaches: a review","volume":"216","author":"Srivastava","year":"2021","journal-title":"Eur J Med Chem"},{"issue":"10","key":"10.1016\/j.zefq.2023.04.004_b0065","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1007\/s00115-020-00967-0","article-title":"Fr\u00fch beginnende Demenzen","volume":"91","author":"Pawlowski","year":"2020","journal-title":"Nervenarzt"},{"key":"10.1016\/j.zefq.2023.04.004_b0070","series-title":"Internationale Klassifikation Psychischer St\u00f6rungen ICD-10: Kap. V (F) klinisch\u2013diagnostische Leitlinien","author":"Dilling","year":"2015"},{"key":"10.1016\/j.zefq.2023.04.004_b0075","unstructured":"Deuschl G, Maier W. S3-Leitlinien Demenzen. In: Deutsche Gesellschaft f\u00fcr Neurologie (DGN) & Deutsche Gesellschaft f\u00fcr Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN), editors. Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. www.dgn.org\/leitlinien, 2016 (accessed 18 December 2022)."},{"issue":"05","key":"10.1016\/j.zefq.2023.04.004_b0080","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1055\/a-1370-3142","article-title":"Pr\u00e4diktive Diagnostik der Alzheimer-Demenz","volume":"89","author":"Rostamzadeh","year":"2021","journal-title":"Fortschr Neurol Psychiatr"},{"issue":"6","key":"10.1016\/j.zefq.2023.04.004_b0085","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jalz.2014.01.001","article-title":"Conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease","volume":"10","author":"Jessen","year":"2014","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.zefq.2023.04.004_b0090","unstructured":"Jessen F. Demenzvorstadien \u2013 sind Risikoprofile und Biomarker f\u00fcr individuelle Pr\u00e4diktion geeignet? [Konferenzbeitrag]. In: Frankfurter Forum f\u00fcr gesellschafts- und gesundheitspolitische Grundsatzfragen e.V., editor. Demenz \u2013 neue Ans\u00e4tze in Forschung, Diagnose und Therapie; Frankfurt. Frankfurter Forum f\u00fcr gesellschafts- und gesundheitspolitische Grundsatzfragen e.V.; 2019, 14-19."},{"key":"10.1016\/j.zefq.2023.04.004_b0095","series-title":"Demenzdiagnostik","author":"Stemmler","year":"2018"},{"issue":"9","key":"10.1016\/j.zefq.2023.04.004_b0100","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3390\/brainsci9090213","article-title":"Biomarker-based signature of Alzheimer\u2019s disease in pre-MCI individuals","volume":"9","author":"Chipi","year":"2019","journal-title":"Brain Sci"},{"key":"10.1016\/j.zefq.2023.04.004_b0105","unstructured":"FDA-NIH Biomarker Working Group: BEST (Biomarkers, Endpoints, and other Tools) Resource; 2016. www.ncbi.nlm.nih.gov\/books\/NBK326791\/ (accessed 17 January 2023)."},{"issue":"5","key":"10.1016\/j.zefq.2023.04.004_b0110","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","article-title":"A\/T\/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers","volume":"87","author":"Jack","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.zefq.2023.04.004_b0115","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3389\/fncom.2019.00072","article-title":"Prediction and classification of Alzheimer\u2019s disease based on combined features from apolipoprotein-E genotype, cerebrospinal fluid, MR, and FDG-PET imaging biomarkers","volume":"13","author":"Gupta","year":"2019","journal-title":"Front Comput Neurosci"},{"issue":"7","key":"10.1016\/j.zefq.2023.04.004_b0120","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41582-022-00665-2","article-title":"Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility","volume":"18","author":"Karikari","year":"2022","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"10.1016\/j.zefq.2023.04.004_b0125","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00401-022-02408-5","article-title":"Plasma biomarkers for Alzheimer\u2019s Disease in relation to neuropathology and cognitive change","volume":"143","author":"Smirnov","year":"2022","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.zefq.2023.04.004_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101544","article-title":"Biomarkers used in Alzheimer\u2019s disease diagnosis, treatment, and prevention","volume":"74","author":"Mahaman","year":"2022","journal-title":"Ageing Res Rev"},{"issue":"2","key":"10.1016\/j.zefq.2023.04.004_b0135","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers","volume":"12","author":"Jack","year":"2013","journal-title":"Lancet Neurol"},{"issue":"14","key":"10.1016\/j.zefq.2023.04.004_b0140","doi-asserted-by":"crossref","first-page":"e1295","DOI":"10.1212\/WNL.0000000000006277","article-title":"Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease","volume":"91","author":"McDade","year":"2018","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.zefq.2023.04.004_b0145","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3233\/JAD-160722","article-title":"Cerebrospinal fluid A\u03b2 42\/40 corresponds better than A\u03b2 42 to amyloid PET in Alzheimer\u2019s Disease","volume":"55","author":"Lewczuk","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.zefq.2023.04.004_b0150","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10354-021-00848-4","article-title":"Neuropathologie der Demenzen","volume":"171","author":"Klotz","year":"2021","journal-title":"Wien Klin Wochenschr"},{"issue":"9","key":"10.1016\/j.zefq.2023.04.004_b0155","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1007\/s00115-020-00907-y","article-title":"Fr\u00fcherkennung der Alzheimer-Krankheit und Demenzpr\u00e4diktion bei Patienten mit leichter kognitiver St\u00f6rung: Zusammenfassung aktueller Empfehlungen","volume":"91","author":"Rostamzadeh","year":"2020","journal-title":"Nervenarzt"},{"issue":"10043","key":"10.1016\/j.zefq.2023.04.004_b0160","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","article-title":"Alzheimer's disease","volume":"388","author":"Scheltens","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.zefq.2023.04.004_b0165","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3233\/JAD-160037","article-title":"The role of cerebrospinal fluid biomarkers in the evolution of diagnostic criteria in Alzheimer\u2019s disease: shortcomings in prodromal diagnosis","volume":"53","author":"Szal\u00e1rdy","year":"2016","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"10.1016\/j.zefq.2023.04.004_b0170","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jalz.2016.09.009","article-title":"Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment","volume":"13","author":"Herukka","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.zefq.2023.04.004_b0175","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s13760-017-0816-5","article-title":"Alzheimer\u2019s disease CSF biomarkers: clinical indications and rational use","volume":"117","author":"Niemantsverdriet","year":"2017","journal-title":"Acta Neurol Belg"},{"issue":"11","key":"10.1016\/j.zefq.2023.04.004_b0180","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jalz.2018.07.220","article-title":"Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease","volume":"14","author":"Shaw","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.zefq.2023.04.004_b0185","first-page":"1","article-title":"Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)","volume":"6","author":"Ritchie","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.zefq.2023.04.004_b0190","first-page":"1","article-title":"CSF tau and the CSF tau\/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)","volume":"3","author":"Ritchie","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.zefq.2023.04.004_b0195","first-page":"1","article-title":"18F PET with florbetapir for the early diagnosis of Alzheimer\u2019s disease dementia and other dementias in people with mild cognitive impairment (MCI)","volume":"11","author":"Mart\u00ednez","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.zefq.2023.04.004_b0200","first-page":"1","article-title":"18F-FDG PET for the early diagnosis of Alzheimer\u2019s disease dementia and other dementias in people with mild cognitive impairment (MCI)","volume":"1","author":"Smailagic","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.zefq.2023.04.004_b0205","first-page":"1","article-title":"Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment","volume":"3","author":"Lombardi","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.zefq.2023.04.004_b0210","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0197-4580(98)00022-0","article-title":"Consensus report of the working group on: \u201cMolecular and biochemical markers of Alzheimer\u2019s disease\u201c","volume":"19","author":"The Ronald National Institute on Aging Working Group","year":"1998","journal-title":"Neurobiol Aging"},{"issue":"6","key":"10.1016\/j.zefq.2023.04.004_b0215","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jalz.2014.11.001","article-title":"2014 Update of the Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception","volume":"11","author":"Weiner","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.zefq.2023.04.004_b0220","series-title":"Handbuch Methoden der empirischen Sozialforschung","first-page":"691","article-title":"Qualitative Inhaltsanalyse","author":"Mayring","year":"2022"},{"issue":"1","key":"10.1016\/j.zefq.2023.04.004_b0225","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13195-022-00971-3","article-title":"Considerations regarding a diagnosis of Alzheimer\u2019s disease before dementia: a systematic review","volume":"14","author":"Van der Schaar","year":"2022","journal-title":"Alzheimer's Res Ther"},{"issue":"2","key":"10.1016\/j.zefq.2023.04.004_b0230","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s11673-018-9844-y","article-title":"Review of the ethical issues of a biomarker-based diagnoses in the early stage of Alzheimer\u2019s disease","volume":"15","author":"Vanderschaeghe","year":"2018","journal-title":"J Bioeth Inq"},{"key":"10.1016\/j.zefq.2023.04.004_b0235","first-page":"123","article-title":"Alzheimer\u2019s disease \u2013 why we need early diagnosis","author":"Rasmussen","year":"2019","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"10.1016\/j.zefq.2023.04.004_b0240","doi-asserted-by":"crossref","first-page":"158","DOI":"10.14283\/jpad.2020.19","article-title":"Rationale for early diagnosis of mild cognitive impairment (MCI) supported by emerging digital technologies","volume":"7","author":"Sabbagh","year":"2020","journal-title":"J Prev Alzheimer's Dis"},{"issue":"4","key":"10.1016\/j.zefq.2023.04.004_b0245","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3233\/JAD-180638","article-title":"Ethical arguments concerning the use of Alzheimer\u2019s disease biomarkers in individuals with no or mild cognitive impairment: a systematic review and framework for discussion","volume":"66","author":"Smedinga","year":"2018","journal-title":"J Alzheimer's Dis"},{"issue":"3","key":"10.1016\/j.zefq.2023.04.004_b0250","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3390\/jpm10030114","article-title":"Biomarkers for Alzheimer\u2019s disease early diagnosis","volume":"10","author":"Aus\u00f3","year":"2020","journal-title":"J Pers Med"},{"issue":"7","key":"10.1016\/j.zefq.2023.04.004_b0255","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3390\/medicina58070906","article-title":"The knowledge and attitudes of primary care and the barriers to early detection and diagnosis of Alzheimer\u2019s disease","volume":"58","author":"De Levante","year":"2022","journal-title":"Medicina"},{"issue":"5_Part_2","key":"10.1016\/j.zefq.2023.04.004_b0260","doi-asserted-by":"crossref","first-page":"450","DOI":"10.7326\/0003-4819-139-5_Part_2-200309021-00014","article-title":"Healthy aging and dementia: findings from the Nun Study","volume":"139","author":"Snowdon","year":"2003","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.zefq.2023.04.004_b0265","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/brain\/awz142","article-title":"Persistent neuropathological effects 14 years following amyloid-\u03b2 immunization in Alzheimer\u2019s disease","volume":"142","author":"Nicoll","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.zefq.2023.04.004_b0270","doi-asserted-by":"crossref","DOI":"10.1038\/news030310-15","article-title":"Alzheimer's vaccine setback confirmed","author":"Check","year":"2003","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.zefq.2023.04.004_b0275","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3233\/JAD-161252","article-title":"Cerebrospinal fluid biomarkers and clinical progression in patients with subjective cognitive decline and mild cognitive impairment","volume":"58","author":"Wolfsgruber","year":"2017","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"10.1016\/j.zefq.2023.04.004_b0280","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/alz.12379","article-title":"Bayes analysis supports null hypothesis of anti-amyloid beta therapy in Alzheimer's disease","volume":"17","author":"Richard","year":"2021","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.zefq.2023.04.004_b0285","article-title":"Aducanumab: European agency rejects Alzheimer\u2019s drug over efficacy and safety concerns","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.zefq.2023.04.004_b0290","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"Van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.zefq.2023.04.004_b0295","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1001\/archneur.65.8.1091","article-title":"Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study","volume":"65","author":"O\u2019Bryant","year":"2008","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.zefq.2023.04.004_b0300","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000089218","article-title":"The clinical dementia rating sum of box score in mild dementia","volume":"21","author":"Lynch","year":"2006","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"1","key":"10.1016\/j.zefq.2023.04.004_b0305","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s15202-023-5614-8","article-title":"Diskussion um Lecanemab: Zeitenwende f\u00fcr die Alzheimer-Therapie oder kaum sp\u00fcrbarer Effekt?","volume":"24","author":"M\u00fcller","year":"2023","journal-title":"DNP"},{"issue":"11","key":"10.1016\/j.zefq.2023.04.004_b0310","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1136\/jnnp-2019-321913","article-title":"Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials","volume":"91","author":"Yu","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Zeitschrift f\u00fcr Evidenz, Fortbildung und Qualit\u00e4t im Gesundheitswesen"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1865921723000697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1865921723000697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T08:04:20Z","timestamp":1761725060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1865921723000697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":62,"alternative-id":["S1865921723000697"],"URL":"https:\/\/doi.org\/10.1016\/j.zefq.2023.04.004","relation":{},"ISSN":["1865-9217"],"issn-type":[{"value":"1865-9217","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kontroverse um die Alzheimer-Fr\u00fchdiagnostik \u2013 eine literaturbasierte \u00dcbersicht \u00fcber die Vor- und Nachteile","name":"articletitle","label":"Article Title"},{"value":"Zeitschrift f\u00fcr Evidenz, Fortbildung und Qualit\u00e4t im Gesundheitswesen","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.zefq.2023.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}]}}